Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET. The event will be accessible via a live and archived webcast on the company’s Investors section of their website.
Pulmonx is known for its Zephyr® Endobronchial Valve and related systems used extensively in treating severe emphysema/COPD, with over 100,000 valves utilized in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will announce its financial results for Q4 and full year 2022 on February 22, 2023, after market close. The management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been commercially available in over 25 countries and used to treat more than 25,000 patients.
Investors can access a live and archived webcast of the event on the Investors section of the Pulmonx website.
Pulmonx Corporation has partnered with the American Lung Association to enhance education on Endobronchial Valves, a treatment for severe COPD. This initiative focuses on raising awareness among patients and healthcare providers about available treatment options. The campaign aims to empower individuals living with COPD by highlighting the minimally invasive nature of Endobronchial Valves, which can significantly improve quality of life. With over 25,000 patients treated with the Zephyr Valves, this collaboration seeks to expand treatment accessibility and knowledge.
Pulmonx Corporation announced the approval of the Zephyr Endobronchial Valve in Japan for treating severe COPD/emphysema patients. The Japanese Ministry of Health has validated the product following a positive PMDA recommendation, emphasizing significant patient benefits such as improved lung function and quality of life. With over 600,000 Japanese patients suffering from severe COPD, this minimally invasive procedure offers a new alternative to traditional invasive surgeries. Pulmonx aims to collaborate for reimbursement strategies prior to commercialization.
Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast will be available on the company’s investor website.
Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. The Zephyr Valve has gained FDA breakthrough device designation and is available in more than 25 countries.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will participate in two investor conferences in New York. Management will hold a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 8:00 AM ET, with a live webcast available on their website. Additionally, they will engage in investor meetings at the Canaccord Genuity MedTech Forum on November 17, 2022. The company’s Zephyr Valve, used for treating emphysema/COPD, has gained FDA approval and is available in over 25 countries.
Pulmonx Corporation (Nasdaq: LUNG) reported Q3 2022 revenues of $13.5 million, up 2% year-over-year, with U.S. revenue of $8.4 million reflecting a strong 22% growth. The gross margin improved to 75% from 73% a year prior, driven by production efficiencies. However, international revenue fell by 20%.
Net loss widened to $14.2 million or $0.38 per share. The company lowered its full-year 2022 revenue guidance to $51.5 million to $52.5 million from a prior estimate of $55 million to $60 million. Despite challenges, Pulmonx aims to expand its market presence.
Pulmonx Corporation (Nasdaq: LUNG) will announce its third-quarter 2022 financial results on November 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Pulmonx specializes in minimally invasive treatments for lung disease, particularly through its FDA-approved Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. Interested parties are encouraged to register online for the call, which will also be available via live and archived webcast.
Pulmonx Corporation (NASDAQ: LUNG) reported promising interim results from the CONVERT clinical trial presented at the 2022 European Respiratory Society (ERS) International Conference. The trial demonstrated that the AeriSeal System successfully closed collateral air channels in 78% of patients with severe COPD/emphysema, making them eligible for Zephyr Endobronchial Valves. Notable improvements were observed in lung function (FEV1 increase of 19.7%), quality of life (SGRQ score decrease of 15.1), and exercise capacity (Six-Minute Walk Distance increase of 77.2 meters).
Pulmonx Corporation (NASDAQ: LUNG) has announced promising interim results from the CONVERT Study presented at the 2022 European Respiratory Society Conference. The study indicates that the AeriSeal System successfully converted collateral ventilation status in 78% of patients, enabling them to receive Zephyr Valves treatment. The trial demonstrated a mean Target Lobe Volume Reduction of over 1 liter, improving lung function by 19.7%, quality of life, and exercise capacity. No serious adverse reactions were noted in recent studies, marking a significant advancement in the treatment of severe COPD.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
